Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Christakis A, Nowak J, Hamilton MJ, Goldblum JR, Parrack P, Lindeman NI, et al. Molecular profiling of visible polypoid and invisible conventional intestinal-type low-grade dysplasia in patients with idiopathic inflammatory bowel disease. J Clin Pathol. 2024.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15(1):363.

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.

de Hoog S, Walsh TJ, Ahmed SA, Alastruey-Izquierdo A, Alexander BD, Arendrup MC, et al. Reply to Kidd et al., "Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion". J Clin Microbiol. 2024:e0162523.

Gal J, Mosquera JM, Robinson BD, Schlegel PN. Incidental seminoma in nonobstructive azoospermia: a case report. F S Rep. 2024;5(2):211-213.

Ávila-Gómez P, Shingai Y, Dash S, Liu C, Callegari K, Meyer H, et al. Molecular and functional alterations in the cerebral microvasculature in an optimized mouse model of sepsis-associated cognitive dysfunction. bioRxiv. 2024.

Demko N, Geyer JT. Updates on germline predisposition in pediatric hematologic malignancies: What is the role of flow cytometry? Cytometry B Clin Cytom. 2024;106(5):331-346.

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.